|
Alethia Biotherapeutics obtains US patent for use of anti-Siglec-15 antibodies
Pharmaceutical Business Review The patent entitled ‘Polynucleotides and Polypeptide Sequences involved in the Process of Bone Remodeling’, provides broad protection for antibodies that target Siglec-15 and also having osteoclast differentiation or bone resorption inhibitory activity. |
Glenmark files lawsuit in US court for Hydrocortisone Butyrate cream – Myiris.com
LivemintGlenmark files lawsuit in US court for Hydrocortisone Butyrate creamMyiris.comGlenmark Generics Inc, USA the subsidiary of Glenmark Generics has filed a lawsuit in the court of chancery of the state of Delaware against Astellas Pharma Europe B….
Gilead stops leukaemia drug trial early – PharmaTimes
|
Gilead stops leukaemia drug trial early
PharmaTimes The safety profile of the drug was also found to be “acceptable and consistent with prior experience” when combing it with rituximab in previously treated CLL. Norbert Bischofberger, Gilead’s R&D chief, said the firm is pleased that idelalisib has … |
Heptares' StaR platform offers breakthrough solution to challenge associated … – News-Medical.net
|
Heptares’ StaR platform offers breakthrough solution to challenge associated …
News-Medical.net Heptares’ StaR platform offers a breakthrough solution to the main challenge associated with making antibodies against GPCRs: producing purified, properly folded and functional protein when removed from the cell membrane for use as an antigen. Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody …PR Newswire (press release) |
Canton-Potsdam Hospital receives grant for heart failure care – WatertownDailyTimes.com
|
Canton-Potsdam Hospital receives grant for heart failure care
WatertownDailyTimes.com POTSDAM — Canton-Potsdam Hospital has received the last installment of a three-year, $40,000 grant from Excellus BlueCross/BlueShield to help patients with congestive heart failure. The money is used to provide home care for patients after they leave … |
Research and Markets: Onartuzumab (Non-Small Cell Lung Cancer) – Forecast … – The Herald | HeraldOnline.com
Research and Markets: Onartuzumab (Non-Small Cell Lung Cancer) – Forecast …The Herald | HeraldOnline.comSales forecast for Onartuzumab for the top nine countries from 2012 to 2022. – Sales information covered for the US, France, Germany, Italy, Spain…
5 Things to Know for Your New Day – Thursday, October 10 – CNN (blog)
|
5 Things to Know for Your New Day – Thursday, October 10
CNN (blog) Three children from the Spirit Lake Tribe will not reconcile with their mom this week because the Bureau of Indian Affairs social worker is on furlough, according to this report. The government paid $47,000 for a … There’s no money to help the … |
Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody … – HispanicBusiness.com
|
Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody …
HispanicBusiness.com The milestone is based on the generation of a stabilised (StaR(R)) form of the first GPCR target selected by MorphoSys, a key step that will enable its use as an antigen against which novel antibodies can be produced. Heptares will receive an … |
Photos: Srihari's Body Brought To Hyderabad; Celebs Pay Last Respect – Oneindia Entertainment
|
Photos: Srihari’s Body Brought To Hyderabad; Celebs Pay Last Respect
Oneindia Entertainment The mortal remains of Telugu actor Srihari, who died due to liver-related problems at the Leelavathi hospital in Mumbai at 5.35 pm on Wednesday, were brought to his residence in Hyderabad this morning. Many Telugu celebrities, who were shocked by his … |
Pot-bellied people 3.6 times likelier to develop memory loss – Daily News & Analysis
|
Pot-bellied people 3.6 times likelier to develop memory loss
Daily News & Analysis Researchers including an Indian-origin scientist has suggested that people having high amounts of abdominal fat in their middle age are 3.6 times more likely to develop memory loss and dementia later in their life. Neurological scientists at the Rush … |